As the potential of in vivo CAR-T therapy moves closer to clinical reality, biotech innovators are reimagining what’s possible in autoimmune disease. With groundbreaking scientific advances and evolving regulatory perspectives, this next generation of cell therapy could redefine how immune-mediated conditions are treated.
In this episode, Pete Robinson, Therapeutic Strategy Director, Novotech, joins Meredith Landry, Managing Editor, Custom Content, Citeline, to discuss how in vivo CAR-T is opening new possibilities for autoimmune therapies—and what it will take to translate early promise into patient impact.
They explore:
• The breakthrough potential of in vivo CAR-T—and what could make it a true game-changer for autoimmune disorders
• Early lessons from the clinic that are shaping the next phase of development
• How innovators are rethinking trial design and regulatory strategy for this emerging modality
• The partnerships and operational moves that could separate first-movers from fast followers
